Mediated cellular delivery of LNA oligonucleotides

Details Mediated cellular delivery of LNA oligonucleotides Mediated cellular delivery of LNA oligonucleotides

2008-01-18

2011-11-01

Vivlemore, Tracy (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C514S04400A

Reexamination Certificate

active

08048998

ABSTRACT:
The present invention relates to novel modified oligomeric compounds and to methods of making and using such compounds. The invention further relates to methods of enhancing the cellular uptake of oligomeric compounds comprising conjugating a metal chelator to those.

REFERENCES:
patent: 3687808 (1972-08-01), Merigan, Jr. et al.
patent: 4426330 (1984-01-01), Sears
patent: 4534899 (1985-08-01), Sears
patent: 4837028 (1989-06-01), Allen
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5108921 (1992-04-01), Low et al.
patent: 5213804 (1993-05-01), Martin et al.
patent: 5225212 (1993-07-01), Martin et al.
patent: 5227170 (1993-07-01), Sullivan
patent: 5264221 (1993-11-01), Tagawa et al.
patent: 5354844 (1994-10-01), Beug et al.
patent: 5356633 (1994-10-01), Woodle et al.
patent: 5395619 (1995-03-01), Zalipsky et al.
patent: 5416016 (1995-05-01), Low et al.
patent: 5417978 (1995-05-01), Tari et al.
patent: 5432272 (1995-07-01), Benner
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5469854 (1995-11-01), Unger et al.
patent: 5512295 (1996-04-01), Kornberg et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5527528 (1996-06-01), Allen et al.
patent: 5534259 (1996-07-01), Zalipsky et al.
patent: 5540935 (1996-07-01), Miyazaki et al.
patent: 5543152 (1996-08-01), Webb et al.
patent: 5543158 (1996-08-01), Gref et al.
patent: 5547932 (1996-08-01), Curiel et al.
patent: 5556948 (1996-09-01), Tagawa et al.
patent: 5580575 (1996-12-01), Unger et al.
patent: 5583020 (1996-12-01), Sullivan
patent: 5591721 (1997-01-01), Agrawal et al.
patent: 5595756 (1997-01-01), Bally et al.
patent: 5665710 (1997-09-01), Rahman et al.
patent: 5705188 (1998-01-01), Junichi et al.
patent: 5770713 (1998-06-01), Imbach et al.
patent: 6043060 (2000-03-01), Imanishi
patent: 6268490 (2001-07-01), Imanishi et al.
patent: 6670461 (2003-12-01), Nielsen et al.
patent: 6794499 (2004-09-01), Wengel et al.
patent: 6887906 (2005-05-01), Teng et al.
patent: 2002/0068709 (2002-06-01), Orum et al.
patent: 2002/0177150 (2002-11-01), Manoharan et al.
patent: 2006/0094045 (2006-05-01), Chang et al.
patent: 0 445 131 (1991-09-01), None
patent: 0 496 813 (1992-08-01), None
patent: 1 072 679 (2001-01-01), None
patent: WO 88/04924 (1988-07-01), None
patent: WO 90/04384 (1990-05-01), None
patent: WO 91/05545 (1991-05-01), None
patent: WO 93/24510 (1993-12-01), None
patent: WO 94/20073 (1994-09-01), None
patent: WO 94/26764 (1994-11-01), None
patent: WO 96/10391 (1996-04-01), None
patent: WO 96/40062 (1996-12-01), None
patent: WO 97/04787 (1997-02-01), None
patent: WO 97/12896 (1997-04-01), None
patent: WO 97/13499 (1997-04-01), None
patent: WO 97/30731 (1997-08-01), None
patent: WO 98/39352 (1998-09-01), None
patent: WO 99/14226 (1999-03-01), None
patent: WO 00/56746 (2000-09-01), None
patent: WO 00/56748 (2000-09-01), None
patent: WO 00/66604 (2000-11-01), None
patent: WO 01/00641 (2001-01-01), None
patent: WO 01/07455 (2001-02-01), None
patent: WO 2004/016274 (2004-02-01), None
U.S. Appl. No. 08/886,829, filed Jul. 1, 1997, Teng et al.
U.S. Appl. No. 09/082,624, filed May 21, 1998, Teng et al.
U.S. Appl. No. 09/256,515, filed Feb. 23, 1999, Hardee et al.
U.S. Appl. No. 09/315,298, filed May 20, 1999, Teng et al.
Adams et al., “Hindered Dialkylamino Nucleoside Phosphite Reagents in the Synthesis of Two DNA 51-Mers,”J. Am. Chem. Soc. 105:661-663 (1983).
Allen et al., “Large Unilamellar Liposomes with Low Uptake Into the Reticuloendothelial System,”FEBS Lett. 223:42-46 (1987).
Andres et al., “New 4′-Functionalized 2,2′:6′,2″-Terpyridines for Applications in Macromolecular Chemistry and Nanoscience,”Eur. J. Org. Chem. 19:3769-3776 (2003).
Babu et al., “Optimized DNA Targeting Using N,N-Bis(2-Pyridylmethyl)-β-Alanyl 2′- Amino-LNA,”Chem. Commun. Issue 13, pp. 1705-1707 (2005).
Berge et al., “Pharmaceutical Salts,”J. Pharm. Sci. 66:1-19 (1977).
Blume et al., “Liposomes for the Sustained Drug Release in Vivo,”Biochim. Biophys. Acta1029:91-97 (1990).
Buur et al., “Penetration of 5-Fluorouracil and Prodrugs Across the Intestine of the Albino Rabbit: Evidence for Shift in Absorption Site from the Upper to Lower Region of the Gastrointestinal Tract by Prodrugs,”Journal of Controlled Release14:43-51 (1990).
Caruthers et al., “Chemical Synthesis and Biological Studies on Mutated Gene-Control Regions,”Cold Spring Harbor Symp. Quant. Biol. 47(Pt. 1):411-418 (1983).
Constantinides et al., “Formulation and Intestinal Absorption Enhancement Evaluation of Water-in-Oil Microemulsions Incorporating Medium-Chain Glycerides,”Pharm. Res. 11:1385-1390 (1994).
Cook, “Medicinal Chemistry of Antisense Oligonucleotides-Future Opportunities,”Anti-Cancer Drug Design6:585-607 (1991).
Dheur et al., “Polyethylenimine but Not Cationic Lipid Improves Antisense Activity of 3′-Capped Phosphodiester Oligonucleotides,”Antisense Nucleic Acid Drug Dev. 9:515-525 (1999).
du Plessis et al., “Topical Delivery of Liposomally Encapsulated Gamma-Interferon,”Antiviral Res.18:259-265 (1992).
El-Hariri et al., “The Mitigating Effects of Phosphatidylcholines on Bile Salt- and Lysophospatidycholine-Induced Membrane Damage,”J. Pharm. Pharmacol. 44:651-654 (1992).
Englisch et al., “Chemically Modified Oligonucleotides as Probes and Inhibitors,”Angew. Chem. Int. Ed. Engl. 30:613-629 (1991).
Freier et al., “The Ups and Downs of Nucleic Acid Duplex Stability: Structure-Stability Studies on Chemically Modified DNA:RNA Duplexes,”Nuc. Acids Res. 25:4429-4443 (1997).
Füssl et al., “Cellular Uptake of PNA-Terpyridine Conjugates and Its Enhancement by Zn2+Ions,”J. Am. Chem. Soc. 128:5986-5987 (2006).
Gabizon et al., “Liposome Formulations with Prolonged Circulation Time in Blood and Enhanced Uptake by Tumors,”Proc. Natl. Acad. Sci. U.S.A. 85:6949-6953 (1988).
Gait, “Peptide-Mediated Cellular Delivery of Antisense Oligonucleotides and Their Analogues,”Cell. Mol. Life Sci. 60:844-853 (2003).
Gall et al., “Formation and Detection of RNA-DNA Hybrid Molecules in Cytological Preparations,”Proc. Natl. Acad. Sci. U.S.A. 63:378-383 (1969).
Guckian et al., “Factors Contributing to Aromatic Stacking in Water: Evaluation in the Context of DNA,”J. Am. Chem. Soc. 122:2213-2222 (2000).
Håkansson et al., “Convenient Synthesis of 7-Hydrox-1-(Hydroxymethyl)-3-(Thymin-1-yl)-2,5-Dioxabicyclo[2.2.1] Heptanes: α-L-Ribo- and α-L-Xylo-Configured LNA Nucleosides,”J.Org. Chem. 65:5161-5166 (2000).
Håkansson et al., “The Adenine Derivative of α-L-LNA (α-L-RiboConfigured Locked Nucleic Acid): Synthesis and High-Affinity Hybridization Towards DNA, RNA, LNA, and αL-LNA Complementary Sequences,”Bioorg. Med. Chem. Lett. 11:935-938 (2001).
Ho et al., “Preparation of Microemulsions Using Polyglycerol Fatty Acid Esters as Surfactant for the Delivery of Protein Drugs,”J. Pharm. Sci. 85:138-143 (1996).
Hu et al., “Topical Delivery of Cyclosporine A from Non-Ionic Liposomal Systems: An In Vivo/In Vitro Correlation Study Using Hairless Mouse Skin,”S.T.P. Pharma Sci. 4:466-469 (1994).
Illum et al., “The Organ Uptake of Intravenously Administered Colloidal Particles Can be Altered Using a Non-Ionic Surfactant (Poloxamer 338),”FEBS Lett. 167:79-82 (1984).
Inoue et al., “Efficient Site-Specific Cleavage of RNA Using a Terpyridine-Copper(II) Complex Joined to a 2'-O-Methyloligonucleotide by a Non-Flexible Linker,”Chem. Commun. Issue 1, pp. 45-46 (1999).
Jarrett, “Affinity Chromatography with Nucleic Acid Polymers,”J. Chromatography618:315-339 (1993).
John et al., “RNA-DNA Hybrids at the Cytological Level,”Nature223:582-587 (1969).
Klibanov et al., “Amphipathic Polyethyleneglycols Effectively Prolong the Circulation Time of Liposomes,”

Affiliated with

Also associated with

Rating

Mediated cellular delivery of LNA oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mediated cellular delivery of LNA oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mediated cellular delivery of LNA oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4281858